2013年10月18日,国家食品药品监督管理总局发布第57期《药品不良反应信息通报》,提示别嘌醇引起重症药疹的安全问题。别嘌醇(Allopurinol)为次黄嘌呤的异构体,是黄嘌呤氧化酶(XO)的抑制剂,可阻止次黄嘌呤和黄嘌呤代谢为尿酸,从而减少尿酸的生成,是目前唯一能抑制尿酸合成的药物,在高尿酸血症等症的治疗领域发挥着重要作用。临床主要用于治疗:①原发性和继发性高尿酸血症,尤其是尿酸生成过多而引 On October 18, 2013, the State Food and Drug Administration released No. 57 “Adverse Drug Reaction Information”, prompting the safety of allopurinol to cause severe drug eruption. Allopurinol, an isomer of hypoxanthine, is an inhibitor of xanthine oxidase (XO), which blocks the metabolism of hypoxanthine and xanthine to uric acid, thereby reducing the production of uric acid, the only inhibitor of hypoxanthine Uric acid synthesis of drugs, in the treatment of hyperuricemia embolism play an important role. Clinical mainly for the treatment: ① primary and secondary hyperuricemia, especially excessive uric acid generated lead